• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping.非酒精性脂肪性肝病、2 型糖尿病和肥胖之间的因果关系对疾病亚表型有影响。
J Hepatol. 2020 Aug;73(2):263-276. doi: 10.1016/j.jhep.2020.03.006. Epub 2020 Mar 10.
2
Blood Levels of the Hepatokine Are Not Causally Linked with Type 2 Diabetes: A Bidirectional Mendelian Randomization Study.血清肝细胞素水平与 2 型糖尿病之间不存在因果关系:一项双向孟德尔随机化研究。
Nutrients. 2021 Nov 24;13(12):4208. doi: 10.3390/nu13124208.
3
Mendelian randomization explores the causal relationships between obesity, diabetes, inflammation and nonalcoholic fatty liver disease.孟德尔随机化探讨肥胖、糖尿病、炎症和非酒精性脂肪性肝病之间的因果关系。
Medicine (Baltimore). 2023 Sep 22;102(38):e34638. doi: 10.1097/MD.0000000000034638.
4
I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.PNPLA3基因中的I148M变异体可降低中心性肥胖和代谢疾病风险,但会增加非酒精性脂肪性肝病的患病几率。
Liver Int. 2015 Dec;35(12):2537-46. doi: 10.1111/liv.12909. Epub 2015 Jul 23.
5
Non-alcoholic fatty liver disease and complications in type 1 and type 2 diabetes: A Mendelian randomization study.1 型和 2 型糖尿病中非酒精性脂肪性肝病及其并发症的孟德尔随机研究。
Diabetes Obes Metab. 2023 Feb;25(2):365-376. doi: 10.1111/dom.14877. Epub 2022 Nov 2.
6
PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.非酒精性脂肪性肝病、肥胖症和糖尿病前期患者的 PNPLA3 I148M 多态性。
J Gastrointestin Liver Dis. 2019 Dec 9;28(4):433-438. doi: 10.15403/jgld-506.
7
Causal relationship between sleep apnea and non-alcoholic fatty liver disease: A Mendelian randomization study.睡眠呼吸暂停与非酒精性脂肪性肝病之间的因果关系:一项孟德尔随机化研究。
Eur J Clin Invest. 2024 Mar;54(3):e14116. doi: 10.1111/eci.14116. Epub 2023 Nov 2.
8
Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study.非酒精性脂肪性肝病与 2 型糖尿病:观察性和孟德尔随机化研究。
Front Endocrinol (Lausanne). 2023 May 8;14:1156381. doi: 10.3389/fendo.2023.1156381. eCollection 2023.
9
Type 1 diabetes mellitus and non-alcoholic fatty liver disease: a two-sample Mendelian randomization study.1 型糖尿病和非酒精性脂肪性肝病:两样本孟德尔随机研究。
Front Endocrinol (Lausanne). 2024 Apr 12;15:1315046. doi: 10.3389/fendo.2024.1315046. eCollection 2024.
10
Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.载脂蛋白基因 I148M 及 TM6SF2 基因 E167K 变异与非酒精性脂肪性肝病患者冠心病风险的独立及联合相关性。
Lipids Health Dis. 2020 Feb 24;19(1):29. doi: 10.1186/s12944-020-01207-9.

引用本文的文献

1
Investigating the Mediating Role of Cardiometabolic Traits in the Causal Link Between SHBG Levels and Stroke Risk via Network Mendelian Randomization.通过网络孟德尔随机化研究心血管代谢特征在性激素结合球蛋白水平与中风风险因果关系中的中介作用。
Curr Issues Mol Biol. 2025 Jun 27;47(7):494. doi: 10.3390/cimb47070494.
2
PNPLA3 I148M variant is the main driver of weight gain after hepatitis C cure.PNPLA3 I148M变异体是丙型肝炎治愈后体重增加的主要驱动因素。
Sci Rep. 2025 Jul 15;15(1):25543. doi: 10.1038/s41598-025-11085-9.
3
Genetic research on MASLD: New insights into cardiovascular disease and cancer risk.非酒精性脂肪性肝病的遗传学研究:对心血管疾病和癌症风险的新见解。
ILIVER. 2024 Aug 10;3(3):100108. doi: 10.1016/j.iliver.2024.100108. eCollection 2024 Sep.
4
Association between cumulative uric acid exposure and metabolic dysfunction-associated fatty liver disease.累积尿酸暴露与代谢功能障碍相关脂肪性肝病之间的关联。
BMC Gastroenterol. 2025 Jul 1;25(1):497. doi: 10.1186/s12876-025-04038-z.
5
Mendelian randomization in cancer research: opportunities and challenges.癌症研究中的孟德尔随机化:机遇与挑战
Infect Agent Cancer. 2025 Jun 15;20(1):37. doi: 10.1186/s13027-025-00672-0.
6
A Biological-Systems-Based Analyses Using Proteomic and Metabolic Network Inference Reveals Mechanistic Insights into Hepatic Lipid Accumulation: An IMI-DIRECT Study.一项基于蛋白质组学和代谢网络推断的生物系统分析揭示了肝脏脂质积累的机制性见解:一项IMI-DIRECT研究。
medRxiv. 2025 Jun 2:2025.06.02.25328773. doi: 10.1101/2025.06.02.25328773.
7
Development and Validation of Machine Learning-Based Marker for Early Detection and Prognosis Stratification of Nonalcoholic Fatty Liver Disease.基于机器学习的非酒精性脂肪性肝病早期检测和预后分层标志物的开发与验证
Adv Sci (Weinh). 2025 Sep;12(33):e10527. doi: 10.1002/advs.202410527. Epub 2025 May 28.
8
The Patatin-Like Phospholipase Domain-Containing 3 148M Variant Exacerbates Alcohol-Induced Liver Injury and Tumorigenesis in Mice.含Patatin样磷脂酶结构域3的148M变体加剧小鼠酒精性肝损伤和肿瘤发生。
Am J Pathol. 2025 May 9. doi: 10.1016/j.ajpath.2025.04.014.
9
Metabolic dysfunction-associated steatotic liver disease in adults.成人代谢功能障碍相关脂肪性肝病
Nat Rev Dis Primers. 2025 Mar 6;11(1):14. doi: 10.1038/s41572-025-00599-1.
10
The combined impact of BMI and ABSI on all-cause mortality among American adults with diabetes.体重指数(BMI)和体脂率表面积指数(ABSI)对美国成年糖尿病患者全因死亡率的综合影响。
Diabetol Metab Syndr. 2025 Feb 7;17(1):48. doi: 10.1186/s13098-025-01614-x.

本文引用的文献

1
Mistaken Identity: Missed Diagnosis of Type 1 Diabetes in an Older Adult.身份误认:老年1型糖尿病的漏诊
Med Res Arch. 2019 Aug;7(8). Epub 2019 Aug 15.
2
Towards Precision Medicine in Nonalcoholic Fatty Liver Disease with PNPLA3 as a Therapeutic Target.以PNPLA3为治疗靶点的非酒精性脂肪性肝病精准医学研究
Gastroenterology. 2019 Oct;157(4):1156-1157. doi: 10.1053/j.gastro.2019.08.003. Epub 2019 Aug 7.
3
Liver Function and Risk of Type 2 Diabetes: Bidirectional Mendelian Randomization Study.肝功能与 2 型糖尿病风险:双向孟德尔随机研究。
Diabetes. 2019 Aug;68(8):1681-1691. doi: 10.2337/db18-1048. Epub 2019 May 14.
4
PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice.载脂蛋白 L3、CGI-58 与肝内甘油三酯水解的抑制作用。
Hepatology. 2019 Jun;69(6):2427-2441. doi: 10.1002/hep.30583. Epub 2019 Apr 9.
5
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis.非酒精性脂肪性肝病与糖尿病。第一部分:流行病学和诊断。
Diabetes Metab J. 2019 Feb;43(1):31-45. doi: 10.4093/dmj.2019.0011.
6
Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.用反义寡核苷酸沉默 Pnpla3 可改善 Pnpla3 I148M 敲入小鼠的非酒精性脂肪性肝炎和肝纤维化。
Mol Metab. 2019 Apr;22:49-61. doi: 10.1016/j.molmet.2019.01.013. Epub 2019 Feb 5.
7
Adiposity in relation to risks of fatty liver, cirrhosis and liver cancer: a prospective study of 0.5 million Chinese adults.肥胖与脂肪肝、肝硬化和肝癌风险的关系:对 50 万中国成年人的前瞻性研究。
Sci Rep. 2019 Jan 28;9(1):785. doi: 10.1038/s41598-018-36460-7.
8
Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients.非酒精性脂肪性肝病的瘦患者具有与肥胖患者相似的严重组织学表型。
J Clin Med. 2018 Dec 17;7(12):562. doi: 10.3390/jcm7120562.
9
Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption.提高两样本汇总数据孟德尔随机化的准确性:超越 NOME 假设。
Int J Epidemiol. 2019 Jun 1;48(3):728-742. doi: 10.1093/ije/dyy258.
10
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?从非酒精性脂肪性肝病到糖尿病的往返之旅:分子靶点来拯救?
Acta Diabetol. 2019 Apr;56(4):385-396. doi: 10.1007/s00592-018-1266-0. Epub 2018 Dec 5.

非酒精性脂肪性肝病、2 型糖尿病和肥胖之间的因果关系对疾病亚表型有影响。

Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping.

机构信息

Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.

Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.

出版信息

J Hepatol. 2020 Aug;73(2):263-276. doi: 10.1016/j.jhep.2020.03.006. Epub 2020 Mar 10.

DOI:10.1016/j.jhep.2020.03.006
PMID:32165250
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7371536/
Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D) and obesity are epidemiologically correlated with each other but the causal inter-relationships between them remain incompletely understood. We aimed to explore the causal relationships between the 3 diseases.

METHODS

Using both UK Biobank and publicly available genome-wide association study data, we performed a 2-sample bidirectional Mendelian randomization analysis to test the causal inter-relationships between NAFLD, T2D, and obesity. Transgenic mice expressing the human PNPLA3-I148M isoforms (TghPNPLA3-I148M) were used as an example to validate causal effects and explore underlying mechanisms.

RESULTS

Genetically driven NAFLD significantly increased the risk of T2D and central obesity but not insulin resistance or generalized obesity, while genetically driven T2D, body mass index and WHRadjBMI causally increased NAFLD risk. The animal study focusing on PNPLA3 corroborated these causal effects: compared to the TghPNPLA3-I148I controls, the TghPNPLA3-I148M mice developed glucose intolerance and increased visceral fat, but maintained normal insulin sensitivity, reduced body weight, and decreased circulating total cholesterol. Mechanistically, the TghPNPLA3-I148M mice demonstrated decreased pancreatic insulin but increased glucagon secretion, which was associated with increased pancreatic inflammation. In addition, transcription of hepatic cholesterol biosynthesis pathway genes was significantly suppressed, while transcription of thermogenic pathway genes was activated in subcutaneous and brown adipose tissues but not in visceral fat in TghPNPLA3-I148M mice.

CONCLUSIONS

Our study suggests that lifelong, genetically driven NAFLD causally promotes T2D with a late-onset type 1-like diabetic subphenotype and central obesity; while genetically driven T2D, obesity, and central obesity all causally increase the risk of NAFLD. This causal relationship revealed new insights into how nature and nurture drive these diseases, providing novel hypotheses for disease subphenotyping.

LAY SUMMARY

Non-alcoholic fatty liver disease, type 2 diabetes and obesity are epidemiologically correlated with each other, but their causal relationships were incompletely understood. Herein, we identified causal relationships between these conditions, which suggest that each of these closely related diseases should be further stratified into subtypes. This is important for accurate diagnosis, prevention and treatment of these diseases.

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)、2 型糖尿病(T2D)和肥胖症在流行病学上相互关联,但它们之间的因果关系尚不完全清楚。我们旨在探讨这 3 种疾病之间的因果关系。

方法

利用英国生物银行(UK Biobank)和公开的全基因组关联研究数据,我们进行了 2 样本双向孟德尔随机化分析,以检验 NAFLD、T2D 和肥胖症之间的因果关系。我们使用表达人 PNPLA3-I148M 同工型的转基因小鼠(TghPNPLA3-I148M)作为示例来验证因果效应并探索潜在机制。

结果

遗传驱动的 NAFLD 显著增加了 T2D 和中心性肥胖的风险,但不增加胰岛素抵抗或全身性肥胖的风险,而遗传驱动的 T2D、体重指数和 WHRadjBMI 则可因果性地增加 NAFLD 的风险。针对 PNPLA3 的动物研究证实了这些因果关系:与 TghPNPLA3-I148I 对照相比,TghPNPLA3-I148M 小鼠发生葡萄糖不耐受和内脏脂肪增加,但保持正常的胰岛素敏感性、降低体重和降低循环总胆固醇。从机制上看,TghPNPLA3-I148M 小鼠表现出胰腺胰岛素减少但胰高血糖素分泌增加,这与胰腺炎症增加有关。此外,TghPNPLA3-I148M 小鼠肝脏胆固醇生物合成途径基因的转录显著受抑制,而皮下和棕色脂肪组织的产热途径基因的转录被激活,但内脏脂肪中的基因转录未被激活。

结论

本研究表明,终生遗传驱动的 NAFLD 可因果性地促进 T2D,表现为迟发性 1 型样糖尿病表型和中心性肥胖;而遗传驱动的 T2D、肥胖和中心性肥胖均会增加 NAFLD 的风险。这种因果关系为这些疾病的“天性”和“教养”如何驱动它们提供了新的见解,并为疾病的亚表型提供了新的假说。

非专业人士,仅供参考